EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial

Steven R Sarkisian, Robert E Ang, Andy M Lee, John P Berdahl, Sebastian B Heersink, James H Burden, Long V Doan, Kerry G Stephens, David Applegate, Angela C Kothe, Dale W Usner, L Jay Katz und 1 weitere

Ophthalmology and Therapy · 2024-04 · 13 (4) · 995-1014

DOI: 10.1007/s40123-024-00898-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 12.02.2024. Verfasst von Steven R Sarkisian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oklahoma Eye Surgeons, PLLC, 5600 N Portland Avenue, Oklahoma City, OK, 73112, USA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This prospective, multicenter, randomized, double-masked pivotal phase 3 trial evaluated the efficacy and safety of the travoprost intracameral SE-implant (slow-eluting implant, the intended commercial product) and FE-implant (fast-eluting implant, included primarily for masking purposes) compared to twice-daily (BID) timolol ophthalmic solution, 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: The trial enrolled adult patients with OAG or OHT with an unmedicated mean diurnal intraocular pressure (IOP) of ≥ 21 and unmedicated IOP ≤ 36 mmHg at each diurnal timepoint (8 A.M., 10 A.M., and 4 P.M.) at baseline. The eligible eye of each patient was administered an SE-implant, an FE-implant or had a sham administration procedure. Patients who received an implant were provided placebo eye drops to be administered BID and patients who had the sham procedure were provided timolol eye drops to be administered BID. The primary efficacy endpoint, for which the study was powered, was mean change from baseline IOP at 8 A.M. and 10 A.M. at day 10, week 6, and month 3. Non-inferiority was achieved if the upper 95% confidence interval (CI) on the difference in IOP change from baseline (implant minus timolol) was < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints. The key secondary endpoint was mean change from baseline IOP at 8 A.M. and 10 A.M. at month 12. Non-inferiority at month 12 was achieved if the upper 95% CI was < 1.5 mmHg at both timepoints. Safety outcomes included treatment-emergent adverse events (TEAEs) and ophthalmic assessments. RESULTS: A total of 590 patients were enrolled at 45 sites and randomized to one of three treatment groups: 197 SE-implant (the intended commercial product), 200 FE-implant, and 193 timolol. The SE-implant was non-inferior to timolol eye drops in IOP lowering over the first 3 months, and was also non-inferior to timolol at months 6, 9, and 12. The FE-implant was non-inferior to timolol over the first 3 months, and also at months 6 and 9. Of those patients who were on glaucoma medication at screening, a significantly greater proportion of patients in the SE- and FE-implant groups (83.5% and 78.7%, respectively) compared to the timolol group (23.9%) were on fewer topical glaucoma medications at month 12 compared to screening (P < 0.0001, chi-square test). TEAEs, mostly mild, were reported in the study eyes of 39.5% of patients in the SE-implant group, 34.0% of patients in the FE-implant group and 20.1% of patients in the timolol group. CONCLUSIONS: The SE-travoprost intracameral implant demonstrated non-inferiority to timolol over 12 months whereas the FE-implant demonstrated non-inferiority over 9 months. Both implant models were safe and effective in IOP lowering in patients with OAG or OHT. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03519386.

Schlagwörter

Stichwörter der Autor:innen

Intraocular pressureOcular drug delivery systemOcular hypertensionOpen-angle glaucomaTravoprost intracameral implantiDose® TR

Autor:innen und Institutionen

  • Oklahoma Eye Surgeons, PLLC, 5600 N Portland Avenue, Oklahoma City, OK, 73112, USA.
  • Asian Eye Institute, 8th to 10th Floor, Rockwell Center, PHINMA Plaza Building, 01200, Makati City, Philippines.
  • Total Eye Care, 388 E. Hwy 67, Duncanville, TX, 75137, USA.
  • Vance Thompson Vision, 3101 West 57th Street, Sioux Falls, SD, 57108, USA.
  • Eye Center South, DBA Trinity Research Group, 2800 Ross Clark Circle, Dothan, AL, 36301, USA.
  • Skyline Vision Clinic and Laser Center, 3155 North Union Boulevard, Colorado Springs, CO, 80907, USA.

Zitieren

APA

Sarkisian, S. R., Ang, R. E., Lee, A. M., Berdahl, J. P., Heersink, S. B., Burden, J. H., Doan, L. V., Stephens, K. G., Applegate, D., Kothe, A. C., Usner, D. W., Katz, L. J., & Navratil, T. (2024). Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. Ophthalmology and Therapy, 13(4), 995-1014. https://doi.org/10.1007/s40123-024-00898-y

Vancouver

Sarkisian SR, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, et al. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. Ophthalmology and Therapy. 2024;13(4):995-1014. doi:10.1007/s40123-024-00898-y

BibTeX
@article{Sarkisian2024,
  author = {Sarkisian, Steven R and Ang, Robert E and Lee, Andy M and Berdahl, John P and Heersink, Sebastian B and Burden, James H and Doan, Long V and Stephens, Kerry G and Applegate, David and Kothe, Angela C and Usner, Dale W and Katz, L Jay and Navratil, Tomas},
  title = {Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial},
  journal = {Ophthalmology and Therapy},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {995--1014},
  doi = {10.1007/s40123-024-00898-y}
}
Kostenlos starten →